Anders Jakobsen1,2, Fahimeh Andersen3, Anders Fischer4, Lars H Jensen1, Jens C R Jørgensen5, Ole Larsen6, Jan Lindebjerg7, John Pløen1, Søren R Rafaelsen8,2, Jesper Vilandt9. 1. a Department of Oncology , Vejle Hospital , Vejle , Denmark. 2. i Institute for Regional Health Research, University of Southern Denmark , Odense , Denmark. 3. e Department of Oncology , Hillerød Hospital , Hillerød , Denmark. 4. h Department of Surgical Gastroenterology , Herlev Hospital , Herlev , Denmark. 5. d Department of Surgery , Vejle Hospital , Vejle , Denmark. 6. g Department of Oncology , Herlev Hospital , Herlev , Denmark. 7. b Department of Pathology , Vejle Hospital , Vejle , Denmark. 8. c Department of Radiology , Vejle Hospital , Vejle , Denmark. 9. f Department of Surgery , Hillerød Hospital , Hillerød , Denmark.
Abstract
BACKGROUND: Neoadjuvant chemotherapy has proven valuable in several tumors, but it has not been elucidated in colon cancer. The present phase II trial addressed the issue in high-risk patients selected by computed tomography (CT) scan. MATERIAL AND METHODS: Patients with resectable colon cancer fulfilling the following criteria were offered inclusion; Histopathological verification of adenocarcinoma, T3 tumor on CT scan with extramural tumor invasion > 5 mm or T4 tumor, age ≥ 18 years, PS ≤ 2, adequate hematology, and informed consent. Patients with KRAS, BRAF or PIK3CA mutation or unknown mutational status received three cycles of capecitabine 2000 mg/m(2) days 1-14 q3w and oxaliplatin 130 mg iv day 1 q3w. Wild-type patients received the same chemotherapy supplemented with panitumumab 9 mg/kg iv q3w. After the operation, patients fulfilling the international criteria for adjuvant chemotherapy, i.e. high-risk stage II and III patients, received five cycles of the same chemotherapy without panitumumab. Patients not fulfilling the criteria were offered follow-up only. The primary endpoint was the fraction of patients not fulfilling the criteria for adjuvant chemotherapy (converted patients). Secondary endpoints were recurrence rate, disease-free survival (DFS), and toxicity. RESULTS: The study included 77 patients. The conversion rate was 42% in the wild-type group compared to 51% in patients with a mutation. The cumulative recurrence rate in converted versus unconverted patients was 6% versus 32% (p = 0.005) translating into a three-year DFS of 94% versus 63% (p = 0.005). CONCLUSION: Neoadjuvant chemotherapy in colon cancer is feasible and the results suggest that a major part of the patients can be spared adjuvant chemotherapy. Validation in a randomized trial is warranted.
BACKGROUND: Neoadjuvant chemotherapy has proven valuable in several tumors, but it has not been elucidated in colon cancer. The present phase II trial addressed the issue in high-risk patients selected by computed tomography (CT) scan. MATERIAL AND METHODS:Patients with resectable colon cancer fulfilling the following criteria were offered inclusion; Histopathological verification of adenocarcinoma, T3 tumor on CT scan with extramural tumor invasion > 5 mm or T4 tumor, age ≥ 18 years, PS ≤ 2, adequate hematology, and informed consent. Patients with KRAS, BRAF or PIK3CA mutation or unknown mutational status received three cycles of capecitabine 2000 mg/m(2) days 1-14 q3w and oxaliplatin 130 mg iv day 1 q3w. Wild-type patients received the same chemotherapy supplemented with panitumumab 9 mg/kg iv q3w. After the operation, patients fulfilling the international criteria for adjuvant chemotherapy, i.e. high-risk stage II and III patients, received five cycles of the same chemotherapy without panitumumab. Patients not fulfilling the criteria were offered follow-up only. The primary endpoint was the fraction of patients not fulfilling the criteria for adjuvant chemotherapy (converted patients). Secondary endpoints were recurrence rate, disease-free survival (DFS), and toxicity. RESULTS: The study included 77 patients. The conversion rate was 42% in the wild-type group compared to 51% in patients with a mutation. The cumulative recurrence rate in converted versus unconverted patients was 6% versus 32% (p = 0.005) translating into a three-year DFS of 94% versus 63% (p = 0.005). CONCLUSION: Neoadjuvant chemotherapy in colon cancer is feasible and the results suggest that a major part of the patients can be spared adjuvant chemotherapy. Validation in a randomized trial is warranted.
Authors: Ahmed N Dehal; Amanda N Graff-Baker; Brooke Vuong; Daniel Nelson; Shu-Ching Chang; David Y Lee; Melanie Goldfarb; Anton J Bilchik Journal: J Gastrointest Surg Date: 2018-05-22 Impact factor: 3.452
Authors: Rathin Gosavi; Clemente Chia; Michael Michael; Alexander G Heriot; Satish K Warrier; Joseph C Kong Journal: Int J Colorectal Dis Date: 2021-05-04 Impact factor: 2.571
Authors: Devi Mukkai Krishnamurty; Alexander T Hawkins; Katerina O Wells; Matthew G Mutch; Mathew L Silviera; Sean C Glasgow; Steven R Hunt; Sekhar Dharmarajan Journal: J Gastrointest Surg Date: 2018-02-09 Impact factor: 3.452
Authors: Hersh A Ham-Karim; Henry Okuchukwu Ebili; Kirsty Manger; Wakkas Fadhil; Narmeen S Ahmad; Susan D Richman; Mohammad Ilyas Journal: Mol Diagn Ther Date: 2019-06 Impact factor: 4.074